Seres Therapeutics, Inc. financial data

Symbol
MCRB on Nasdaq
Industry
Pharmaceutical Preparations
Location
200 Sidney Street, Cambridge, MA
State of incorporation
DE
Fiscal year end
December 31
Former names
Seres Health, Inc. (to 5/14/2015)
Latest financial report
10-K - Q4 2024 - Mar 13, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 136 % -42.5%
Quick Ratio 37.2 %
Debt-to-equity -1K % +42.7%
Return On Equity -0.5 % -100%
Return On Assets 0.06 %
Operating Margin -65.5K % -104193%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 174M shares +15.5%
Common Stock, Shares, Outstanding 173M shares +28.1%
Entity Public Float 87.1M USD -81.2%
Common Stock, Value, Issued 173K USD +28.1%
Weighted Average Number of Shares Outstanding, Basic 155M shares +21.4%
Weighted Average Number of Shares Outstanding, Diluted 155M shares +21.4%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 374K USD -99.7%
Research and Development Expense 64.6M USD -45.1%
General and Administrative Expense 53.2M USD -31.4%
Operating Income (Loss) -121M USD +37.8%
Nonoperating Income (Expense) -4.46M USD -190%
Income Tax Expense (Benefit) 0 USD
Net Income (Loss) Attributable to Parent 136K USD +62.1%
Earnings Per Share, Basic 0 USD/shares +71%
Earnings Per Share, Diluted 0 USD/shares +71%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 30.8M USD -75.9%
Inventory, Net 53M USD +892%
Assets, Current 38.7M USD -78%
Property, Plant and Equipment, Net 11.5M USD -34.5%
Operating Lease, Right-of-Use Asset 80.9M USD -10.5%
Other Assets, Noncurrent 31K USD -98.6%
Assets 140M USD -61%
Accounts Payable, Current 4.08M USD +12%
Employee-related Liabilities, Current 7.66M USD -53.5%
Liabilities, Current 41.2M USD -58.2%
Operating Lease, Liability, Noncurrent 83M USD -9.48%
Other Liabilities, Noncurrent 1.84M USD +12.9%
Liabilities 126M USD -68.8%
Accumulated Other Comprehensive Income (Loss), Net of Tax 0 USD
Retained Earnings (Accumulated Deficit) -978M USD +0.01%
Stockholders' Equity Attributable to Parent 13.8M USD
Liabilities and Equity 140M USD -61%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -35.2M USD +54%
Net Cash Provided by (Used in) Financing Activities 18.8M USD +232%
Net Cash Provided by (Used in) Investing Activities 2.74M USD -78.9%
Common Stock, Shares Authorized 360M shares +50%
Common Stock, Shares, Issued 173M shares +28.1%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -68.2M USD -156%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 39.5M USD -71%
Interest Paid, Excluding Capitalized Interest, Operating Activities 3.58M USD +106%
Deferred Tax Assets, Valuation Allowance 310M USD -0.98%
Deferred Tax Assets, Gross 331M USD -3.25%
Operating Lease, Liability 91.6M USD -5.76%
Payments to Acquire Property, Plant, and Equipment 62K USD -98.5%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent 136K USD +62.1%
Lessee, Operating Lease, Liability, to be Paid 138M USD -22.3%
Property, Plant and Equipment, Gross 64.7M USD -2.94%
Operating Lease, Liability, Current 8.67M USD +55.3%
Lessee, Operating Lease, Liability, to be Paid, Year Two 20M USD -9.42%
Lessee, Operating Lease, Liability, to be Paid, Year One 19.4M USD -2.15%
Operating Lease, Weighted Average Discount Rate, Percent 0.13 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 46.2M USD -28.9%
Lessee, Operating Lease, Liability, to be Paid, Year Three 20.6M USD -9.23%
Deferred Tax Assets, Operating Loss Carryforwards 156M USD +9.58%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Unrecognized Tax Benefits 14M USD +3.59%
Lessee, Operating Lease, Liability, to be Paid, Year Four 20.9M USD -10.6%
Operating Lease, Payments 17.3M USD +10.7%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization 5.47M USD -12.4%
Share-based Payment Arrangement, Expense 21M USD -38.5%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%